DUBLIN, November 7, 2022 /PRNewswire/ — The “Global Osteoporosis Drugs Market, Size, Forecast 2022-2027, Industry Trends, Growth, Impact of COVID-19, Opportunities Company Analysis” Report has been added to ResearchAndMarkets.com offering.
The global market for osteoporosis drugs is projected to reach $16.43 billion in 2027. Osteoporosis is a chronic and life-threatening disorder in which the microstructure of the bones is altered due to a reduction in bone mass and bone density. Also, this condition leads to increased bone fragility and the threat of cracks and bone fractures. There is no cure for osteoporosis, and as such, the FDA has approved medications to prevent, slow, or stop the progress of osteoporosis. In addition, taking prescription osteoporosis medications, along with other healthy lifestyle behaviors such as getting enough calcium, vitamin D, and regular exercise, helps reduce the risk of bone fractures (also called fractures) due to osteoporosis throughout the body. world.
Global Market for Osteoporosis Drugs Reached $12.01 billion in 2021
Surprisingly, since there is no other substitute available to treat osteoporosis (such as surgery), the pharmaceutical industry is an unavoidable part of osteoporosis treatment throughout the world. Globally, the osteoporosis drug market is primarily driven by a significant increase in the prevalence of the osteoporosis disorder. In addition, an unprecedented increase in the prevalence of osteoporosis translates into a high demand for drugs to prevent and treat osteoporosis, thus expanding the potential for growth in the forecast years. In addition, it is assumed that the population of older people throughout the world that has a high susceptibility to osteoporosis increases the high demand for drugs for osteoporosis.
The drug classes have been successful and are expected to continue to be successful during the forecast period:
The drug classes currently being marketed in the osteoporosis space are all antiresorptive therapies. These include bisphosphonates, selective estrogen inhibitors (SERMs), parathyroid hormone therapy, calcitonin, and ligand-ranking inhibitors. Based on our analysis, the drug classes have been successful since the mid-1990s and we expect them to continue to be successful during the forecast period.
However, there has been a significant paradigm shift in development strategies for drug development for late- and mid-stage osteoporosis. Pharmaceutical companies have focused their attention on the design of anabolic drugs rather than antiresorptive therapies. Anabolic drugs act against the progression of osteoporosis in the opposite way to antiresorptives by stimulating new bone formation rather than delaying bone resorption.
Injectable route of administration is accelerating growth in the market:
The osteoporosis drug market is categorized into oral and injectable by route of administration. The oral route of administration leads the market due to the increased adoption of oral drugs. Alongside this, the increase in the consumption of oral drugs is further affecting a more significant production, which is positively influencing the growth of the market over the years. In contrast, the injectable route of administration segment is anticipated to accelerate its growth during the forecast period. In addition, the launch of some new biosimilar is more convenient for its consumption without any risk in the treatment of osteoporosis.
By Types, Brand and Generic Osteoporosis Drugs controls the global Osteoporosis Drugs market:
In our report, we have covered generic and brand name osteoporosis drugs by type. While the brand name osteoporosis drug will certainly retain a stronghold in the industry paradigm, its status as the gold standard will be increasingly challenged by generic osteoporosis drugs entering the market. Therefore, we anticipate that the demand for generic osteoporosis drugs will undergo a fundamental change with their increasing preference by consumers in the market. Looking at market trends, we expect consumers to gravitate towards generic osteoporosis drugs, which will be available in abundance during the forecast period.
Regional perspectives: North America bills for a lion’s share
North America represents a predominant share of the overall market. In addition, several collaborative efforts by major companies to enhance their R&D capabilities and ensure high medical standards are expected to drive demand for osteoporosis drugs throughout the US region. In addition, the majority participation can also be attributed to the high burden of disease in North America.
On the contrary, the Pacific Asia The market is expected to grow at a lucrative rate during the forecast years. According to our estimates, the high growth recorded by the Pacific Asia it is believed to be a consequence of the continued R&D investments made by prominent players and their efforts to market generic and brand name therapies at a relatively low price. According to the publisher, Global Osteoporosis Drugs Industry is posting a CAGR of 5.4% during 2021-2027.
Drug Class – The market has been covered from 6 points of view:
The Administration Route – Drug Market has been approached from 3 points of view:
Type – Market has been approached from 2 points of view:
Region – The market has been covered from 5 points of view:
middle East Y Africa
Key Topics Covered:
2. Research methodology
3. Executive Summary
4. Market dynamics
5. Global Market for Osteoporosis Drugs
6. Market Share – Global Osteoporosis Drug Market
7. Drug Class – Global Osteoporosis Drug Market
8. Route of Administration – Global Osteoporosis Drug Market
9. Type – Global Osteoporosis Drug Market
10. Region – Lithium Ion Battery Market
11. Porters Five Forces
12. Company analysis
For more information on this report, visit https://www.researchandmarkets.com/r/6lceuh
Research and Markets
laura woodSenior manager
For business hours EST call +1-917-300-0470
For US/Canada call toll free +1-800-526-8630
For GMT business hours call +353-1-416-8900
US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716
SOURCE Research and Markets